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Summary 
Background Ovarian cancer has a high case–fatality ratio, with most women not diagnosed until the disease is in its 
advanced stages. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a randomised 
controlled trial designed to assess the eﬀ ect of screening on mortality. This report summarises the outcome of the 
prevalence (initial) screen in UKCTOCS. 
Methods Between 2001 and 2005, a total of 202 638 post-menopausal women aged 50–74 years were randomly 
assigned to no treatment (control; n=101 359); annual CA125 screening (interpreted using a risk of ovarian cancer 
algorithm) with transvaginal ultrasound scan as a second-line test (multimodal screening [MMS]; n=50 640); or 
annual screening with transvaginal ultrasound (USS; n=50 639) alone in a 2:1:1 ratio using a computer-generated 
random number algorithm. All women provided a blood sample at recruitment. Women randomised to the MMS 
group had their blood tested for CA125 and those randomised to the USS group were sent an appointment to attend 
for a transvaginal scan. Women with abnormal screens had repeat tests. Women with persistent abnormality on 
repeat screens underwent clinical evaluation and, where appropriate, surgery. This trial is registered as 
ISRCTN22488978 and with ClinicalTrials.gov, number NCT00058032.
Findings In the prevalence screen, 50 078 (98·9%) women underwent MMS, and 48 230 (95·2%) underwent USS. 
The main reasons for withdrawal were death (two MMS, 28 USS), non-ovarian cancer or other disease (none 
MMS, 66 USS), removal of ovaries (ﬁ ve MMS, 29 USS), relocation (none MMS, 39 USS), failure to attend three 
appointments for the screen (72 MMS, 757 USS), and participant changing their mind (483 MMS, 1490 USS). 
Overall, 4355 of 50 078 (8.7%) women in the MMS group and 5779 of 48 230 (12·0%) women in the USS group 
required a repeat test, and 167 (0·3%) women in the MMS group and 1894 (3·9%) women in the USS group 
required clinical evaluation. 97 of 50 078 (0·2%) women from the MMS group and 845 of 48 230 (1·8%) from the 
USS group underwent surgery. 42 (MMS) and 45 (USS) primary ovarian and tubal cancers were detected, including 
28 borderline tumours (eight MMS, 20 USS). 28 (16 MMS, 12 USS) of 58 (48·3%; 95% CI 35·0–61·8) of the 
invasive cancers were stage I/II, with no diﬀ erence (p=0·396) in stage distribution between the groups. A further 
13 (ﬁ ve MMS, eight USS) women developed primary ovarian cancer during the year after the screen. The sensitivity, 
speciﬁ city, and positive-predictive values for all primary ovarian and tubal cancers were 89·4%, 99·8%, and 43·3% 
for MMS, and 84·9%, 98·2%, and 5·3% for USS, respectively. For primary invasive epithelial ovarian and tubal 
cancers, the sensitivity, speciﬁ city, and positive-predictive values were 89·5%, 99·8%, and 35·1% for MMS, and 
75·0%, 98·2%, and 2·8% for USS, respectively. There was a signiﬁ cant diﬀ erence in speciﬁ city (p<0·0001) but not 
sensitivity between the two screening groups for both primary ovarian and tubal cancers as well as primary 
epithelial invasive ovarian and tubal cancers.
Interpretation The sensitivity of the MMS and USS screening strategies is encouraging. Speciﬁ city was higher 
in the MMS than in the USS group, resulting in lower rates of repeat testing and surgery. This in part 
reﬂ ects the high prevalence of benign adnexal abnormalities and the more frequent detection of 
borderline tumours in the USS group. The prevalence screen has established that the screening strategies are 
feasible. The results of ongoing screening are awaited so that the eﬀ ect of screening on mortality can be 
determined.
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Introduction 
Ovarian cancer is a disease with a poor prognosis. 
Although advances in therapy have improved median 
survival during the past decade, there has been little or 
no change in the overall mortality rate.1,2 Women are 
commonly diagnosed with stage III/IV disease, for which 
5-year survival rates are around 27% and 16%, 
respectively.3–5 This has led to eﬀ orts over the past two 
decades to develop early detection strategies using serum 
CA125 and ultrasound.6,7 Preliminary evidence from a 
previous randomised controlled trial suggests that 
screening sequentially with CA125 and ultrasound 
(multimodal screening) can result in a survival beneﬁ t.8 
Median survival was signiﬁ cantly increased in women 
who developed ovarian cancer in the screened group 
compared with the control group (72·9 vs 41·8 months, 
p=0·0112). Improved survival has also been reported in a 
single-arm ultrasound-based study.9 
Reﬁ nements have been made to screening since the 
two previous studies, including the introduction of 
transvaginal ultrasound,10 improvements in the inter-
pretation of ultrasound ﬁ ndings using morphology-based 
indices,9,11–13 and the development of a risk of ovarian 
cancer algorithm for the interpretation of serial CA125 
results.14,15 
The multicentre United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) is a randomised 
controlled trial designed to provide deﬁ nitive data on the 
eﬀ ect of ovarian cancer screening on mortality, as well as 
comprehensively addressing the cost, acceptance, 
physical and psychosocial morbidity, and performance 
characteristics of multimodal screening and ultrasound-
based screening.
Methods 
Participants
Women were recruited through 13 regional trial centres 
located in National Health Service (NHS) Trusts in 
England, Wales, and Northern Ireland.16 All women 
provided written consent. Eligibility criteria included age 
50–74 years, and postmenopausal status deﬁ ned as 
greater than and including 12 months, amenorrhoea 
following a natural or surgical menopause, or greater 
than and including 12 months of hormone-replacement 
therapy commenced for menopausal symptoms.17 
Women were excluded if they had a history of bilateral 
oophorectomy, active malignancy (women with a past 
history of malignancy were eligible if they had no 
documented persistent or recurrent disease and had not 
received treatment for >12 months), previous history of 
ovarian cancer, participation in other ovarian cancer 
screening trials, or increased risk of familial ovarian 
cancer. High-risk women were eligible for a separate 
trial: the United Kingdom Familial Ovarian Cancer 
Screening Study (UKFOCSS).18
The study was approved by the UK North West 
Multicentre Research Ethics Committee (00/8/34), with 
site-speciﬁ c approval from the local regional ethics 
committees and the Caldicott guardians (data controllers) 
of the participating Primary Care Trusts.
Procedures
Invitations to participate in the trial were sent to women 
aged 50–74 years whose details were obtained from the 
age and sex registers of the participating 27 Primary Care 
Trusts.16 On enrolment at the trial centres, women viewed 
an information video and participated in a group 
discussion before completing a datasheet, consent forms, 
and undergoing venepuncture. The recruitment question-
naires were sent to the coordinating centre, where they 
were scanned electronically using com puterised 
intelligent character-reading and optical-mark-reading 
software (Teleform Elite version 8.1.1, Cardiﬀ  Software 
Inc, Vista, CA, USA). Any inconsistency or information 
not recognised by the data-capture software was veriﬁ ed 
manually by trained data-entry staﬀ , who validated the 
computer-interpreted data. Once the custom-built trial-
management system conﬁ rmed eligibility, participants 
were randomly assigned to either no treatment (control); 
annual CA125 screening (interpreted using a patented 
risk-of-ovarian-cancer algorithm) with transvaginal 
ultrasound scan as a second-line test (multimodal 
screening; MMS); or annual screening with transvaginal 
ultrasound (USS) alone in a 2:1:1 ratio with a computer-
generated random number algorithm. 
Randomisation was done as follows: ﬁ rst, the trial 
management system allocated a set of 32 random 
numbers to each trial centre; second, the lowest eight 
were allocated to the MMS group, the next eight to the 
USS group, and the remaining 16 to the control group; 
third, each successive volunteer within the trial centre 
was randomly allocated one of the random numbers and 
so randomly assigned a group; and ﬁ nally, when all 
32 random numbers had been used up a further set 
of 32 was generated. Randomisation was accomplished 
by the trial-management system using the visual basic 
randomisation statement and the Rnd function.
Panel 1: Classiﬁ cation of ovarian morphology on ultrasound
Normal
• Ovary of uniform hypoechogenicity and with a smooth 
outline with or without a single inclusion cyst or spots of 
calciﬁ cations
• Inclusion cyst must be single, less than 10 mm in diameter 
and not distort the outline of the ovary
Simple cyst
• A single, thin walled, anechoic cyst with no septa or 
papillary projections
Complex 
• Any case in which the ovary has any non-uniform ovarian 
echogenicity, excluding single simple or inclusion cysts
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Following randomisation, letters were automatically 
printed and sent to each woman and their general 
practitioner conﬁ rming eligibility and randomisation 
status. Between April, 2001, and October, 2005, 202 638 
women were enrolled in the trial. The women in the 
MMS and USS groups will be screened until Dec 31, 
2011. All women will be followed up until Dec 31, 2014.
Screening tests 
Two screening tests were used. The ﬁ rst was 
measurement of serum CA125. Blood samples were 
taken in gel tubes (8 mL gel separation serum tubes; 
Greiner Bio-One 455071, Stonehouse, UK) at the trial 
centres and transported overnight at ambient 
temperature to the central laboratory. All blood samples 
received more than 56 h after venepuncture were 
discarded and repeat samples requested. The blood was 
centrifuged at 1500g for 10 min and the serum separated. 
Excess serum was stored in aliquots. Serum CA125 
concentrations were determined by electro-
chemiluminescence sandwich immunoassay on an 
Elecsys 2010 (Roche Diagnostics, Burgess Hill, UK) 
using two monoclonal antibodies (OC125 and M11; 
Fujirebio Diagnostics AB, Göteborg, Sweden). 
The other screening test was transvaginal ultrasound 
or, where this was not acceptable to a participant, 
transabdominal scan of the pelvis. The ﬁ rst scan (level 1 
scan), and any repeat level 1 scans needed because of an 
unsatisfactory ﬁ rst scan, were done by type 1 
sonographers, who were certiﬁ ed sonographers, trained 
midwives, or doctors with experience in gynaecological 
scanning who were working in the NHS. All staﬀ  who 
administered scans underwent additional training for 
assessment of postmenopausal ovaries. Level 2 scans 
were done by type 2 sonographers following the detection 
of an abnormality. Type 2 sonographers were experienced 
gynaecologists, radiologists, or senior sonographers 
(usually at superintendent grade in the NHS) with 
particular expertise in gynaecological scanning. Most 
scans were done on a dedicated Kretz SA9900 ultrasound 
machine (Medison, Seoul, South Korea). 
Ovarian morphology and dimensions were assessed 
and volume determined using the formula for an ovoid 
(d1×d2×d3×0·532). Ovarian morphology was classiﬁ ed as 
shown in panel 1. Detailed description of all features—
the number and size of cysts, wall regularity, presence 
and thickness of septae, size of papillations, and 
echogenicity of the ﬂ uid contents—were recorded. Cysts 
and complex morphology were classiﬁ ed pictorially, 
initially using the format reported in the Kentucky 
screening trial,19 and from 2003 onwards using the 
International Ovarian Tumour Analysis (IOTA) 
classiﬁ cation.13
Measurement of the ovary was important to conﬁ rm 
that it had been visualised, and for audit purposes. 
The volume of any ovarian cyst visualised was also 
measured using the above formula. Only cyst volume 
Panel 2: Possible outcomes after level 1 and level 2 screens 
in the MMS group
Level 1 screen
• Normal risk of ovarian cancer score: women returned to 
annual screening, with the next level 1 blood test 
scheduled on the next anniversary of the randomisation 
date
• Intermediate risk of ovarian cancer score: women were 
recalled for a repeat CA125 measurement 12 weeks after 
the screen. The risk of ovarian cancer was recalculated and 
triaged as for the level 1 screen. Any women whose risk of 
ovarian cancer remained intermediate after three CA125 
tests were referred for a level 2 screen
• Elevated risk of ovarian cancer score: women were recalled 
for a level 2 screen in 6–8 weeks, with earlier screens 
arranged where there was a high index of suspicion
Level 2 screen
• Women with a normal transvaginal ultrasound scan result 
and normal or intermediate risk of ovarian cancer 
returned to annual screening, with the next level 1 test on 
the next anniversary of the randomisation date
• Women with a normal transvaginal ultrasound scan result 
but an elevated risk of ovarian cancer, or an unsatisfactory 
scan irrespective of risk of ovarian cancer status, 
underwent a repeat level 2 screen in 6 weeks and were 
triaged again on the basis of the results to annual 
screening or clinical assessment
• Women with an abnormal transvaginal ultrasound scan 
were referred for clinical assessment irrespective of their 
risk of ovarian cancer status
Panel 3: Possible outcomes after level 1 and level 2 screens 
in the USS group
Level 1 screen
• Women with a normal scan returned to annual screening, 
with the next level 1 transvaginal ultrasound scan on the 
next anniversary of the randomisation date
• Women with an unsatisfactory scan result attended 
a repeat level 1 scan in 12 weeks. Women were returned to 
annual screening following two unsatisfactory scans
• Women with an abnormal level 1 scan were referred for 
a level 2 scan in 6–8 weeks, with earlier scans arranged 
where there was a high index of suspicion
Level 2 screen
• Women with a normal level 2 scan returned to annual 
screening, with the next level 1 transvaginal ultrasound 
scan on the next anniversary of the randomisation date
• An unsatisfactory level 2 scan led to a repeat level 2 scan 
in 6 weeks or earlier, and women were triaged on the basis 
of the ﬁ ndings to annual screening or clinical assessment
• Women with an abnormal scan were referred for clinical 
assessment
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was used for scan classiﬁ cation. When ovaries were not 
visualised, the sonographers speciﬁ ed whether a good 
view of iliac vessels had been obtained or a poor view 
owing to obstruction by the bowel, ﬁ broids, pelvic 
varicosities, or for other reasons. Ascites was deﬁ ned as a 
maximum vertical pool measurement of greater than or 
equal to 10 mm. 
Based on the visualisation and morphology of the 
ovaries, the scan was classiﬁ ed as either a normal scan, 
in which both ovaries had normal morphology or simple 
cysts less than 60 cm³, or were not visualised but a good 
view of the iliac vessels was obtained; an unsatisfactory 
scan, in which one or both ovaries were not visualised 
owing to a poor view; or an abnormal scan, in which one 
or both ovaries had complex morphology or simple cysts 
greater than 60 cm³, or ascites.
Scan images were transferred weekly on magneto-
optical discs for central archiving. Trial centres were able 
to request central review of ultrasound images.
Screening strategies 
In the level 1 screen in the MMS group, women 
underwent venepuncture and serum CA125 measure-
ment. The assay results were uploaded directly into the 
trial-management system, which calcu lated the risk of 
ovarian cancer using an algorithm developed 
previously.15,17 The ﬁ rst risk of ovarian cancer deter-
mination was based on a single measurement of CA125 
and the woman’s age-speciﬁ c incidence of ovarian 
cancer. Subsequent calculations of the risk of 
ovarian cancer were based on both the absolute CA125 
concentration and the rate of change in 
CA125 concentration. The risk of ovarian cancer 
summarises, in one number, the information about risk 
of ovarian cancer, therefore simplifying the practical 
implementation of the screening protocol. Women were 
triaged into three risk groups on the basis of their risk 
of ovarian cancer, which determined whether they 
returned to annual screening or went on to have a repeat 
CA125 measurement or level 2 screen (panel 2). Level 2 
screening involved venepuncture for repeat CA125 assay 
and a transvaginal ultrasound scan. The results of the 
level 2 screen triggered three possible courses of action, 
as shown in panel 2.
The initial cutoﬀ s used for intermediate and elevated 
risk of ovarian cancer were greater than or equal to 1/1818 
and greater than or equal to 1/500, respectively. As the 
proportion of women classiﬁ ed into these risk categories 
were less than the proposed 15% and 2%, respectively, 
the cutoﬀ s were revised on April 1, 2005, to greater than 
or equal to 1/3500 and greater than or equal to 1/1000 
after extensive data review by the independent data 
monitoring and ethics and trial steering committees. 
86·4% of the prevalence screen CA125 concentrations 
were classiﬁ ed using the pre-2005 cutoﬀ s. 
Women randomly assigned to the USS group had a 
transvaginal ultrasound scan at their regional trial centre. 
There were three possible courses of action depending 
on the results of the level 1 scan, including referral for a 
level 2 scan, the results of which triggered one of a further 
three courses of action, as shown in panel 3. 
All clinicians were provided written information on the 
risk estimates for malignancy associated with the various 
morphological classiﬁ cations from the IOTA series once 
the estimates had been presented at the annual European 
Society of Gynaecological Oncology meeting in 2003. 
Additionally, clinicians were made aware that women 
who had previously undergone a hysterectomy had an 
increased incidence of adhesions and peritoneal 
pseudocysts that may be reported as multilocular adnexal 
cysts.
Clinical assessment
This was undertaken by a designated clinician and 
included clinical evaluation and investigations as 
appropriate. These included serum CA125 in women in 
the ultrasound group, repeat transvaginal scans and 
doppler studies, CT/MRI of the abdomen and pelvis, 
and occasionally assessment of other tumour markers. 
For women in the MMS group with a normal transvaginal 
ultrasound scan but elevated risk of ovarian cancer, 
clinical assessment included ruling out other causes of 
increased CA125 concentrations. The management plan 
took the views of the individual into account, and also 
accounted for any signiﬁ cant comorbidity, the speciﬁ c 
morphological features of the detected lesion, and 
history of a previous hysterectomy or major pelvic 
surgery that could be responsible for false-positive 
ultrasound appearances.
For women who underwent surgery, the recom-
mendation was removal of both ovaries and fallopian 
tubes for histopathological examination, even if the 
ovaries appeared macroscopically normal. Where pelvic 
adhesions were present and there was an increased risk 
of complications, the clinician could opt to remove only 
the ovary found to have an abnormality on ultrasound 
and not proceed to remove the contra lateral ovary. 
202 638 women all had a 
 blood sample taken 
 at recruitment 
562* withdrew
50 078 (98·9%) underwent
the prevalence screen
48 230 (95·2%) underwent
the prevalence screen
*Reasons for withdrawal
Death (2 MMS; 28 USS)
Non-ovarian cancer or other disease (66 USS)
Removal of ovaries (5 MMS; 29 USS)
Relocation (39 USS)
3 screen appointments not attended
(72 MMS; 757 USS)
Changed mind (483 MMS; 1490 USS)
2409* withdrew
50 639 women
ultrasound (USS) group
101 359 women
control group
50 640 women
multimodal (MMS) group
Figure 1: Randomisation and initial (prevalence) screen
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Hysterectomy was only undertaken where there were 
clear clinical indications. The approach to surgery 
depended on the results of the preoperative 
investigations. The primary intervention in most cases 
was laparoscopy with the intention of performing a 
laparoscopic bilateral salpingo-oophorectomy. A 
laparotomy was undertaken if clinical ﬁ ndings or 
laparoscopy led to a strong suspicion of ovarian cancer, 
or if a laparoscopic procedure was not felt to be 
appropriate for other reasons. Women found to have 
ovarian or tubal cancer at a primary laparoscopic 
procedure underwent a subsequent staging pro cedure.
A follow-up plan was drawn up if, after clinical 
assessment, investigation, and discussion with the 
woman, a decision was made to manage the ﬁ ndings 
conservatively. Most women were followed up with a 
transvaginal ultrasound scan and a serum CA125 
assessment at 3 months with a possible repeat at 
6 months, and returned to annual screening if the 
ﬁ ndings were unchanged at this review. 
Follow-up
All participants are being followed up through a ﬂ agging 
study with the NHS Information Centre for Health and 
Social Care (formerly Oﬃ  ce for National Statistics, 
ONS) in England and Wales, and with the Central 
Services Agency and Cancer Registry in Northern 
Ireland. This provides regular notiﬁ cation of any cancer 
registrations or deaths in the cohort. For the purpose of 
this analysis, up-to-date cancer registration data was 
obtained from the agencies on June 13, 2008. 
Additionally, women continued to attend for subsequent 
annual screens, and those who had been in the trial for 
3·5 years following randomisation were sent follow-up 
questionnaires. 
Conﬁ rmation of diagnosis
Medical records of procedures undertaken after an 
abnormal screen result were obtained. Operative notes 
and histopathology and cytology reports of women who 
underwent surgery were reviewed to conﬁ rm the 
diagnosis. In the case of a diagnosis of cancer, further 
information was obtained, including the discharge 
summary, multidisciplinary team meeting notes, and 
other correspondence. This was also done for all cases of 
women found to have ovarian, tubal, peritoneal, or 
disseminated cancer of unknown origin (International 
Classiﬁ cation of Disease [ICD]-10 codes C56, C57.0, C48.2, 
and C80), through screening, ﬂ agging for cancer 
registration, follow-up questionnaire, or directly from the 
participants. The ﬁ nal diagnosis including the primary 
site, stage, and grade of any cancer was made by an 
independent outcomes committee. Where documentation 
was insuﬃ  cient to arrive at a deﬁ nitive conclusion, further 
information and clariﬁ cation was sought from the team 
who treated the patient. Complex cases were discussed by 
the whole committee and a consensus diagnosis reached. 
Histology review was undertaken only for those cases 
 MMS group (N=50 078) USS group (N=48 230) Overall (N=98 308)
Age (years) at randomisation 60·6 (56·1–66·2) 60·5 (56·0–66·0) 60·6 (56·0–66·1)
Years since last menstruation at randomisation 11·4 (5·3–18·5) 11·2 (5·2–19·0) 11·3 (5·3–18·4)
Duration of HRT use (years) at randomisation if applicable 8·1 (4·6–12·0) 8·2 (4·6–12·1) 8·1 (4·6–12·1)
Duration of OCP use (years) if applicable 5 (2–10) 5 (2–10) 5 (2–10)
Miscarriages (pregnancies <6 months) 0 (0–1) 0 (0–1) 0 (0–1)
Number of children (pregnancies >6 months) 2 (2–3) 2 (2–3) 2 (2–3)
Height (cm) 162·6 (157·5–165·1) 162·6 (157·5–165·1) 162·6 (157·5–165·1)
Weight (kg) 67·6 (60·3–76·2) 67·1 (60·3–76·2) 67·6 (60·3–76·2)
Ethnic origin
White 48 340 (96·5) 46 509 (96·4) 94 849 (96·5)
Black 655 (1·3) 678 (1·4) 1333 (1·4)
Asian 431 (0·9) 419 (0·9) 850 (0·9)
Other 417 (0·8) 384 (0·8) 801 (0·8)
Missing 235 (0·5) 240 (0·5) 475 (0·5)
Hysterectomy 9620 (19·2) 9078 (18·8) 18 698 (19·0)
Ever use of OCP 29 743 (59·4) 29 048 (60·2) 58 791 (59·8)
Use of HRT at recruitment 9379 (18·7) 9046 (18·8) 18 425 (18·7)
Personal history of cancer* 2936 (5·9) 2819 (5·8) 5755 (5·9)
Personal history of breast cancer 1831 (3·7) 1793 (3·7) 3624 (3·7)
Maternal history of ovarian cancer 789 (1·6) 747 (1·5) 1536 (1·6)
Maternal history of breast cancer 3128 (6·2) 3070 (6·4) 6198 (6·3)
Data are median (IQR) or number (%). HRT=hormone-replacement therapy. OCP=oral contraceptive pill. *Includes women who have previously had breast cancer. 
Table 1: Baseline characteristics of UKCTOCS participants who underwent the prevalence screen
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where the pathology report showed ambiguity in relation 
to the site of origin, staging, and grading of the cancer, or 
where there was a discrepancy between the pathology 
report and the national cancer registration.
The hospital notes of women who underwent surgery 
were obtained. All surgical complications were conﬁ rmed 
by review of the surgical and clinical notes by a senior 
trial gynaecological oncologist blinded to the rand-
omisation group. 
Statistical analysis
The primary outcome measure in UKCTOCS is ovarian 
cancer mortality and the primary comparison is based on 
an intention-to-treat analysis between the control group 
and both screened groups combined (MMS plus USS). 
However, as the operating characteristics of the two 
screening groups are diﬀ erent a comparison between the 
control group and an individual screen group (MMS or 
USS) is of equal interest. Randomisation in UKCTOCS 
was completed in October, 2005. Women in the MMS and 
USS groups will be screened until Dec 31, 2011, and all 
women will be followed up until Dec 31, 2014. The design 
provides greater than 90% power to detect a 30% reduction 
in ovarian cancer mortality between the control and 
combined screening groups, and greater than 80% power 
to detect a 30% reduction in mortality between the control 
and either one of the individual screening groups, with 
both comparisons tested at a signiﬁ cance level of 0·05. It is 
important to note that if one of the comparisons (control vs 
MMS or USS) is signiﬁ cant and the other is not, the result 
would not necessarily imply that one method is signiﬁ cantly 
better than the other. Only the direct comparison between 
the two methods will address this issue. If, as anticipated, 
the diﬀ erence in ovarian cancer mortality between the two 
screened groups is modest, then this study will have 
limited power to detect such diﬀ erences. The choice of 
screening strategy will then be based on other outcome 
measures such as sensitivity, positive-predictive value, 
morbidity, quality of life, and health economics.
This paper presents the outcome of the prevalence 
screen in women randomly assigned to either MMS 
or USS. The prevalence screen was deﬁ ned as a single or 
series of serum CA125 assays with or without transvaginal 
ultrasound scan (MMS) or transvaginal ultrasound scan 
alone (USS) culminating in surgery or a return to annual 
screening. The screen was considered positive (screen 
positive) if the woman was referred for surgery and 
negative (screen negative) if the woman was returned to 
annual screening. All women in the cohort were censored 
1 year after their last transvaginal ultrasound scan or 
CA125 serum assay in the prevalence screen. The primary 
outcome measure was primary ovarian or fallopian tube 
cancer (ICD-10 code C56 and C57.0, respectively) 
diagnosed within 12 months of the last scan or serum 
CA125 test in the prevalence screen. Women with primary 
peritoneal cancer (ICD-10 code C48.2) and those with 
ovarian neoplasms of uncertain behaviour (ICD-10 code 
D39.1) were not included in the outcome measure. 
Sensitivity, speciﬁ city, and positive-predictive values were 
calculated for the MMS and USS screens separately and 
in combination. Subgroup analyses of primary invasive 
epithelial ovarian cancers (excluding borderline 
malignancies) were also undertaken. The data was 
analysed with STATA version 10.0. No other analysis of 
these data has been undertaken at the time of writing.
This trial is registered as ISRCTN22488978 and with 
ClinicalTrials.gov, number NCT00058032.
Level 1 screen—CA125 (n=50 078)
Level 2 screen in 6 weeks (n=409)
Abnormal scan irrespective of 
risk of ovarian cancer (n=86)
Clinical assessment (n=151)
Surgery
(n=81)
Other CA
(n=4)
Annual screening (n=49  727)
Normal scan with normal or intermediate 
risk of ovarian cancer (n=167)
Normal scan with elevated risk of ovarian 
cancer or unsatisfactory scan (n=156)
Abnormal scan 
Severe risk of ovarian cancer 
Normal scan with elevated risk of ovarian 
cancer
Unsatisfactory scan with raised or 
intermediate risk of ovarian cancer 
(n=69)
Normal scan with normal or
intermediate risk of ovarian cancer
Unsatisfactory scan with 
normal risk of ovarian cancer
(n=63)
Intermediate risk of ovarian cancer (n=4315)
Intermediate risk of ovarian cancer (n=1008)
Normal risk of ovarian 
cancer (n=49 432)
Elevated risk of ovarian 
cancer (n=327)
Intermediate risk of ovarian cancer (n=96)
[22 W, 4 other CA, 1 D, 1 S, 1 AS] [3 W, 3 other CA, 5 S] 
Repeat level 2 screen in 6 weeks (n=132) 
Repeat CA125 in 12 weeks (n=4121)
Repeat CA125 in 12 weeks (n=979)
316
[1 D] [1 S]
49  432
66
[3 W]
240
63
24
[183 W, 5 other CA, 1 D, 4 S, 1 AS] 
93 [2 W, 1 other CA] 
45 523
3050
859
132 [2 W, 7 other CA, 2 D, 5 S, 8 AS] 
16663
Figure 2: Multimodal screening (MMS) algorithm and outcome of initial screen
Boxes represent tests (green) or results. Numbers inside boxes indicate the number of volunteers undergoing a 
speciﬁ c test or having a certain result. Where a test or result can occur via multiple routes the numbers of volunteers 
per route are indicated on the arrows. Numbers in square brackets indicate volunteers who deviated from the 
protocol and the reason. AS=annual screening. CA=diagnosed with other cancer. D=died. S=surgery. W=withdrew.
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Role of the funding source
The funding bodies had no role in the study design, data 
collection, analysis, interpretation or writing of the 
report. The corresponding author had full access to all 
data in the study. The UKCTOCS investigators had ﬁ nal 
responsibility for the decision to submit the report for 
publication.
Results
The trial proﬁ le is shown in ﬁ gure 1. The most common 
reasons for withdrawal were death (two MMS; 28 USS), 
non-ovarian cancer or other disease (66 USS), removal of 
ovaries (ﬁ ve MMS; 29 USS), relocation (39 USS), failure 
to attend three appointments for the screen (72 MMS; 
757 USS), and participant changing her mind (483 MMS; 
1490 USS). The baseline characteristics of women in the 
prevalence screen are shown in table 1. In accordance 
with good practice for randomised controlled trials we 
did not statistically compare the baseline characteristics 
of the women assigned to the two groups;20,21 the groups 
were well balanced (table 1).
Of the 50 078 women who underwent a prevalence 
screen in the MMS group, 45 523 (90·9%) were classiﬁ ed 
as low risk by the risk of ovarian cancer algorithm and 
returned to annual screening. 240 (0·5%) had an elevated 
risk and were referred for a level 2 screen. 4315 (8·6%) 
women had intermediate risk leading to a recom-
mendation for repeat CA125 testing in 3 months. 169 of 
these intermediate-risk women were referred for a level 2 
screen. 409 (0·8%) women underwent a level 2 screen, 
after which 167 (0·3%) women were referred for clinical 
assessment and 81 proceeded to surgery. Additionally, 
16 women had clinical assessment and surgery following 
an abnormal screen without additional tests, as per 
protocol. Overall, 4555 (9·1%) women required a repeat 
test and 97 (0·2%) had surgery (ﬁ gure 2). In the course of 
the screen, ﬁ ve women in the MMS group died from 
unrelated causes, 24 were diagnosed with cancers other 
than ovarian cancer, and 215 withdrew from the trial.
Of the 48 230 women randomly assigned to the USS 
group, 42 416 (87·9%) had transvaginal ultrasound 
scans, 4325 (9·0%) had transabdominal ultrasound 
scans, and 1489 (3·1%) had both. 42 451 (88·0%) women 
had normal scans and were returned to annual 
screening. 2774 (5·8%) women were found to have 
abnormalities and referred directly for a level 2 screen. 
3005 (6·2%) women had unsatisfactory scans 
necessitating a repeat level 1 scan, and 110 women from 
this group were referred for a level 2 screen. 
Overall, 5779 (12·0%) women in the USS group required 
a repeat test. 2785 (5·8%) women underwent a level 2 
screen. Of these women, 1894 (3·9%) were referred for 
clinical assessment, and 775 women proceeded to 
surgery. Additionally, 70 women had clinical assessment 
and surgery following an abnormal screen without 
additional screens, as per protocol. Overall, 845 (1·8%) 
women in the USS group had surgery (ﬁ gure 3). 
Six women in the USS group died from unrelated causes 
during the course of screening, seven were diagnosed 
with cancers other than ovarian cancer, and 252 withdrew 
from the trial.
Overall, 942 (0·95%) of the 98 308 women screened 
underwent surgery as a result of the prevalence screen, 
with 8·7 women in the USS group undergoing surgery 
for every one woman from the MSS group who underwent 
surgery. The number of operations in the MMS group 
was signiﬁ cantly lower than in the USS group (p<0·005). 
There was a diﬀ erence in surgical approach between the 
two groups, with 75 of 97 (77·3%) operations in the MMS 
group involving laparotomy versus 397 of 845 (46·9%) in 
the USS group (table 2). 834 (47 MMS, 787 USS) women 
who underwent surgery were found to have benign 
pathology or normal ovaries (table 3), of whom 24 (2·9%; 
95% CI 1·7–4·0) experienced a major complication. This 
included two of 47 (4·3%; 95% CI 0·0–10·3) women in 
MMS and 22 of 787 (2·8%; 95% CI 1·65–3·95) women in 
the USS group (table 2). The complications were six cases 
of perforation of a hollow viscus, two cases of excessive 
haemorrhage requiring further surgery, one re-admission 
for portal site pain and surgery to remove an endometriotic 
Level 1 scan (n=48 230)
Unsatisfactory (n=3005)Abnormal (n=2774) Normal (n=42 451)
Level 1 USS scan repeated
Level 2 screen in 6 weeks (n=2785)
Repeat level 2 screen in 6 weeks (n=42)
Abnormal (n=1807) Unsatisfactory (n=45) Normal (n=933)
Abnormal (n=115) Unsatisfactory (n=417) Normal (n=2247)
Abnormal (n=20)
Clinical assessment (n=1824)
Surgery (n=775)
Annual screening (n=47 099)
Unsatisfactory (n=8) Normal (n=14)
2779 [212 W, 5 other CA, 3 D, 2 S, 4 AS] 
110 [5 S] [1 W]
[1 W, 1 S, 1 AS]
20 8
[7 W, 1 other CA, 3 D]
[20 W, 1 other CA, 62 S, 16 AS] 3 W
42448
2663
925[8 W]
14
1049
1796
2675
Figure 3: Ultrasound screening (USS) algorithm and outcome of initial screen
Boxes represent tests (green) or results. Numbers inside boxes indicate the number of volunteers undergoing a 
speciﬁ c test or having a certain result. Where a test or result can occur via multiple routes the numbers of volunteers 
per route are indicated on the arrows. Numbers in square brackets indicate volunteers who deviated from the 
protocol and the reason. AS=annual screening. CA=diagnosed with other cancer. D=died. S=surgery. W=withdrew.
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nodule and residual ovary in left pelvic side wall, one 
pulmonary embolism, two cases of deep-vein thrombosis, 
four cases of wound dehiscence, one wound haematoma, 
two hernias, one signiﬁ cant ileus, one bowel obstruction, 
one bowel ﬁ stula, and two cases of signiﬁ cant infection.
Ovarian or tubal malignancies were detected in 
87 women: 42 in the MMS group and 45 in the USS 
group (table 3). Of these malignancies, eight in the MMS 
group and 20 in the USS group were borderline epithelial 
neoplasms (p=0·013). There was no signiﬁ cant diﬀ erence 
(Fisher’s exact test p=0·229) in the number of stage III 
borderline cancers in the MMS (two of eight) compared 
with the USS group (one of 20). Fewer primary invasive 
epithelial cancers (24 vs 34) were detected in the USS 
than in the MMS group. Overall, 28 of the 58 (48·3%; 
95% CI 35·0–61·8) primary invasive epithelial cancers 
detected were stage I/II. There was no diﬀ erence (Fisher’s 
exact test p=0·396) in the stage distribution between the 
two groups (table 4). 
In the MMS group, 33 (78·6%) of the 42 women with 
ovarian or tubal malignancies had ovarian cancer detected 
as a result of an elevated risk of ovarian cancer on the 
level 1 screen (ﬁ rst blood test). The median time to 
surgery from the level 1 screen in this group was 75·0 days 
(IQR 55·8–114·8). In the USS group, all 45 (100%) 
women had ovarian cancer detected as a result of an 
abnormal scan on the level 1 screen (ﬁ rst scan). The 
median time to surgery from level 1 scan in these women 
was similar to that for women in the MMS group: 
81·5 days (IQR 60·3–112·5). This period included the 
level 2 screen within 42 days, and then referral, clinical 
assessment, and often further imaging before surgery. 
However, nine (21·4%) of the women in the MMS group 
with ovarian or tubal malignancies had ovarian cancer 
detected after an intermediate risk of ovarian cancer at 
the level 1 screen that led to repeat tests. The median 
time to surgery from the level 1 screen in these women 
was 273·9 days (IQR 220·0–331·0), since the protocol for 
managing intermediate risk was to repeat CA125 tests 
MMS (N=50 640) USS (N=50 639) Overall (N=101 279)
Number who underwent the prevalence (ﬁ rst) level 1 screen* 50 078 (98·9%) 48 230 (95·2%) 98 308 (97·1%)
Normal 45 523 (90·9%) 42 451 (88·0%) 87 974 (89·5%)
Intermediate risk of ovarian cancer and unsatisfactory scans 4315 (8·6%) 3005 (6·2%) 7320 (7·4%)
Elevated risk of ovarian cancer and abnormal scan 240 (0·5%) 2774 (5·8%) 3014 (3·1%)
Number women who underwent (ﬁ rst) level 2 screen† 409 (0·8%) 2785 (5·8%) 3194 (3·2%)
Normal 167 (40·8%) 933 (33·5%) 1100 (34·4%)
Abnormal 86 (21·0%) 1807 (64·9%) 1893 (59·3%)
Unsatisfactory 156 (38·1%) 45 (1·6%) 201 (6·3%)
Number of women referred for clinical evaluation 167 (0·3%) 1894 (3·9%) 2070 (2·1%)
Number of women who underwent surgery‡ 97 (0·2%) 845 (1·8%) 942 (1·0%)
Diagnostic laparoscopy 6 (6·2%) 34 (4·0%) 40 (4·2%)
Operative laparoscopy 16 (16·5%) 413 (48·9%) 429 (45·5%)
Diagnostic laparoscopy and laparotomy 6 (6·2%) 80 (9·5%) 86 (9·1%)
Laparotomy 69 (71·1%) 317 (37·5%) 386 (41·0%)
Unknown 0 (0·0%) 1 (0·1%) 1 (0·1%)
*Fisher’s exact test, signiﬁ cant diﬀ erence (p<0·0001) between MMS and USS in results of level 1 screen. †Fisher’s exact test, signiﬁ cant diﬀ erence (p<0·0005) between MMS 
and USS in results of level 2 screen. ‡Fisher’s exact test, signiﬁ cant diﬀ erence (p<0·0001) between MMS and USS in surgical approach. Owing to very large sample sizes, the 
p values tend to imply statistical diﬀ erence where clinically meaningful diﬀ erence is minimal.
Table 2: Outcome of prevalence screen in UKCTOCS
MMS USS Overall
Total surgeries 97 845* 942
Denied access to notes 0 1 1
Diagnostic laparoscopy, ovary normal, not removed 6 34† 40
Normal ovaries 0 15 15
Benign ovarian neoplasm 40 732 772
Ovarian neoplasm of uncertain behaviour (ICD-10 D39.1) 1‡ 5 6
Primary peritoneal cancer (ICD-10 C48.2) 1 1 2
Other non-ovarian cancer 4§ 7¶ 11
Metastatic ovarian cancer 3|| 5** 8
Non-epithelial neoplasm of ovary (ICD-10 C56) 0 1 1
Primary borderline epithelial neoplasm of ovary (ICD-10 C56) 8 20 28
Primary invasive epithelial neoplasm of ovary (ICD-10 C56) 32 23 55
Primary invasive epithelial neoplasm of fallopian tube (ICD-10 C57.0) 2 1 3
Total malignant neoplasms of ovary (ICD-10 C56) and fallopian tube (ICD-10 C57.0) 42 45 87
Screen-negative cancers within 1 year of screen
Borderline epithelial neoplasm of ovary (ICD-10 C56) 1 0 1
Primary invasive epithelial neoplasm of ovary (ICD-10 C56) 4 8 12
Total malignant neoplasm of ovary (ICD-10 C56) and fallopian tube (ICD-10 C57.0) 5 8 13
*One participant refused access to notes, at the time of writing there is no ONS registration of a cancer for this case. 
†One woman was diagnosed with ovarian cancer at a second operation undertaken 22 months after the prevalence 
screen. ‡Patient developed postmenopausal bleeding while waiting for a repeat CA125 test and was diagnosed to have 
synchronous endometrial cancer and ovarian granulosa cell tumour. §Two endometrial cancers, one stomach cancer, 
one follicular lymphoma. ¶Three endometrial cancers, one cervical cancer, one anal cancer, one lymphoma, and one 
multiple myeloma. ||One pancreatic cancer, one colorectal cancer, and one cancer of the appendix. **Three breast 
cancers, one endometrial cancer, and one cancer of the appendix.
Table 3: Histology in women who underwent surgery as a result of screening (screen positives)
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over a period of 8–10 months (ﬁ gure 2). Of the nine 
women with ovarian cancer detected after an intermediate 
risk of ovarian cancer at the level 1 scan, seven had 
abnormal level 2 scans. One woman initially had a 
normal level 2 scan, and one woman had two normal 
level 2 scans but was operated on based on a severe risk 
of ovarian cancer classiﬁ cation. 
Four ovarian cancers have not been included in the 
analysis of performance characteristics as they were 
diagnosed more than 1 year after the last test on the 
prevalence screen. They include one woman in the MMS 
group and two from the USS group who withdrew from 
the trial after their level 1 screen and had an ovarian 
cancer diagnosed more than 1 year later. Additionally, a 
fourth woman had an abnormal prevalence screen in the 
USS group and underwent diagnostic laparoscopy. She 
was thought to have an ovarian ﬁ broma, and her ovaries 
were not removed (table 3). At an incident screen 
22 months later, an increase in size of the mass on 
ultrasound prompted bilateral salpingo-oophorectomy, 
and she was diagnosed with stage IC papillary serous 
cystadenocarcinoma. 
Median follow-up from the last test on the prevalence 
screen to cancer registration update was 4·57 years (IQR 
3·68–5·54). As information on cancers can take up to 3 
years to be recorded by the national cancer registries, we 
explored in detail the other sources of follow-up data in 
the 12 658 women for whom time from censorship 
(1 year from the date of the last scan or CA125 test on the 
prevalence screen) to cancer registry follow up on 
June 13, 2008, was less then 3 years. In this cohort, after 
the censorship date, we had additional conﬁ rmation of 
ovarian cancer status in 11 336 women, as they had 
attended for further screening, and in an additional 
17 women through returned follow-up questionnaires. 
The source of veriﬁ cation of ovarian cancer status was 
limited to cancer registry follow up that was less than 
3 years from the date of censorship in only 1275 women 
(1·3% of the entire cohort; table 5). 
13 additional (interval) ovarian and tubal cancers were 
diagnosed clinically within 1 year of a normal prevalence 
screen result. This included one primary borderline and 
four invasive epithelial ovarian cancers in the MMS 
group, and eight primary invasive epithelial ovarian 
cancers in the USS group (table 3). The CA125 
concentrations at the prevalence screen ranged from 7 to 
24 IU/L in the ﬁ ve women with ovarian and tubal cancers 
in the MMS group, and the cancers were diagnosed at 92, 
204, 254, 294, and 329 days after the screen. All of the 
prevalence scans were normal in the USS group, and the 
cancers were diagnosed at 30, 203, 255, 267, 278, 293, 
301, and 341 days after the screen.
For all primary ovarian and tubal cancers, the 
sensitivity, speciﬁ city, and positive-predictive values for 
MMS and USS screening are shown in table 6. There 
were 2·3 (42 of 97) operations per case of ovarian cancer 
in the MMS and 18·8 (45 of 845) operations per case of 
ovarian cancer in the USS group. There was a signiﬁ cant 
diﬀ erence in speciﬁ city between the two groups 
(p<0·0001), but no diﬀ erence in sensitivity (p=0·564). 
When the analysis was restricted to primary invasive 
epithelial ovarian and tubal cancers, sensitivity was, 
compared with values when all cancers were included 
(table 6), much the same in the MMS group, but lower 
in the USS group, although the diﬀ erence in sensitivity 
between MMS and USS was still not statistically 
signiﬁ cant (p=0·126). 2·9 (34 of 97) operations were 
done per case in the MMS and 35·2 (24 of 845) operations 
per case in the USS group (table 6). 
Discussion 
Both a CA125-based and an ultrasound-based screening 
strategy are feasible on a large scale. On the initial screen, 
almost half of the cancers detected were in stage I/II. 
Screen positive Screen negative
MMS USS Overall MMS USS Overall
Stage
I 14 10 24 3 0 3
II 2 2 4 0 0 0
III 18 10 28 1 7* 8
IV 0 2 2 0 1 1
Early (I/II) stage cancers (%) 47·1% 50·0% 48·3% 75·0% 0·0% 25·0%
Lower 95% CI 29·8% 29·1% 35·0% 19·4% 0·0% 5·5%
Upper 95% CI 64·9% 70·9% 61·8% 99·4% 41·0% 57·2%
Morphology
Serous 21 14 35 0 2 2
Endometrioid 5 3 8 1 0 1
Clear cell 0 5 5 1 0 1
Carcinosarcoma 1 0 1 1 0 1
Adenocarcinoma 7 2 9 1 6 7
Grade
1 3 2 5 0 0 0
2 6 2 8 2 0 2
3 24 14 38 2 6 8
Not graded 1 6 7 0 2 2
*In two cases a diagnosis was made on the basis of ascitic ﬂ uid cytology, omental biopsy, and imaging: primary surgery 
was not undertaken.
Table 4: Characteristics of primary invasive epithelial ovarian and tubal cancers (ICD-10 C56 and C57.0)
MMS (N=50 078) USS (N=48 230) Overall (N=98 308)
ONS follow-up >3 years from censorship date 
or when death certiﬁ cate was available 
45 544 (90·9%) 40 106 (83·2%) 85 650 (87·1%)
Number of women who have had an 
appointment after censorship date*
4071 (8·1%) 7295 (18·2%) 11 366 (11·6%)
Number of women who have completed a 
follow-up questionnaire after censorship date*
4 (0·01%) 13 (0·03%) 17 (0·02%)
Remaining* 459 (0·9%) 816 (1·7%) 1275 (1·3%)
*In women with ONS follow-up <3 years from censorship date. Censorship date is 1 year from the date of the last scan 
or CA125 in the prevalence screen.
Table 5: Details of follow-up of women who underwent screening
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Speciﬁ city was higher in the MMS than in the USS 
group, resulting in fewer repeat tests and almost nine 
times fewer operations per cancer detected. The stage 
distribution of the screen-detected primary invasive 
cancers was similar in both groups. However, more 
borderline epithelial ovarian neoplasms were detected in 
the USS group than in the MMS group. Among missed 
cancers, there were slightly more stage I cancers in the 
MMS than in the USS group. 
To our knowledge, this is the largest randomised 
controlled trial of ovarian cancer screening to date. It is 
also the ﬁ rst ovarian cancer screening trial to randomly 
assign women to two screening strategies, enabling the 
performance of both strategies to be compared directly. 
The prevalence screen involved almost 100 000 women, 
with systematic follow-up to detect missed cancers. The 
main strengths of the study are recruitment by random 
invitation using the health-authority registers of 
27 Primary Care Trusts, the multicentre design involving 
recruitment and screening through 13 NHS Trusts, the 
scale of the trial, high compliance with screening, 
randomisation to two well-deﬁ ned screening strategies, 
and an independent review of surgical outcomes and 
detailed follow-up of the entire cohort. These factors 
provide conﬁ dence about the validity of the ﬁ ndings. 
ICD-10 codes were used when reporting outcomes so 
that comparisons across studies can be made.22 Many 
previous studies have included primary peritoneal 
cancers (ICD-10 C48.2) as true positives,23 while others 
have included ovarian granulosa cell tumours under 
primary ovarian cancers, and have not classiﬁ ed them 
separately as ovarian neoplasm of uncertain behaviour 
(ICD-10 D39.1).9 We have excluded both from our primary 
outcome measure. Although primary peritoneal cancers 
are treated similarly to advanced primary ovarian 
carcinomas, neither the MMS nor the USS screening 
strategies were developed to detect them. However, data 
on these cancers would be interesting, so primary 
peritoneal cancers are listed separately in table 3. By 
contrast, granulosa cell tumours are unlikely to contribute 
signiﬁ cantly to mortality, and their inclusion makes 
comparison with national statistics diﬃ  cult. However, we 
have included primary borderline (low malignant 
potential) ovarian neoplasms, since they share the same 
ICD-10 code (C56) as primary invasive epithelial ovarian 
cancers. Their inclusion is therefore the only way to 
compare trial data with national and international 
incidence and mortality statistics. However, a subgroup 
analysis excluding these cancers has also been 
undertaken. 
84 primary ovarian (ICD-10 C56) and three tubal 
cancers (ICD-10 C57.0) were detected on screening, with 
a further 13 primary ovarian cancers diagnosed clinically 
in the ensuing year. Overall, the total numbers of cases 
were similar, but there was a diﬀ erence in the number 
of borderline cancers between the two groups. 19% 
(eight of 42) of the primary ovarian cancers detected 
were borderline in the MMS group, compared with 15% 
reported in clinical series.24 However, 44% (20 of 45) of 
the primary ovarian cancers detected in the USS group 
were borderline. Borderline ovarian tumours have 
10-year survival rates in excess of 95%.25 Of the 
28 borderline tumours detected, only three were stage 
III. This highlights an issue that has already become a 
signiﬁ cant problem in other cancer-screening 
strategies—the detection of cancers that may never have 
been diagnosed in an individual’s lifetime had they not 
been screened. Overdiagnosis or pseudodisease may be 
thought of as pathological diagnoses detected by 
screening or autopsy, but which have little clinical 
relevance. It could be argued that these cases would be 
best classiﬁ ed as false positives. In cancer screening, 
estimates of overdetection range from 3 to 50% of cases 
in breast cancer screening26 and 22 to 34% in prostate 
cancer screening.27 A similar rate of 25% overdetection 
has been reported with chest radiography for lung 
cancer, with the use of CT expected to result in higher 
rates.28 In ovarian cancer, such false positives may 
include ovarian neoplasms of uncertain behaviour 
(ICD-10 D39.1) and borderline disease. Once borderline 
cancers are detected during screening, it is diﬃ  cult not 
to operate given that borderline and stage I invasive 
 MMS USS Overall p value*
Total
Number of women 50 078 48 230 98 308 ··
Number of surgeries 97 845 942 ··
Primary ovarian and tubal malignancies (ICD-10 C56 and C57.0) within 1 year of prevalence screen†
Screen positives 42 45 87 ··
Screen negatives 5 8 13 ··
Sensitivity 89·4% 84·9% 87·0% 0·564
95% CI 76·9–96·5 72·4–93·3 78·8–92·9 ··
Speciﬁ city 99·8% 98·2% 99·0% <0·0001‡
95% CI 99·8–99·8 98·1–98·4 99·0–99·1 ··
Positive-predictive value 43·3% 5·3% 9·2% ··
95% CI 33·3–53·8 3·9–7·1 7·5–11·3 ··
Number of operations per screen positive 2·3 18·8 10·8 ··
Primary invasive epithelial ovarian and tubal malignancies within 1 year of prevalence screen§
Screen positives 34 24 58 ··
Screen negatives 4 8 12 ··
Sensitivity 89·5% 75·0% 82·9% 0·126
95% CI 75·2–97·1 56·6–88·5 72·0–90·8 ··
Speciﬁ city 99·8% 98·2% 99·0% <0·0001‡
95% CI 99·8–99·8 98·1–98·4 99·0–99·1 ··
Positive-predictive value 35·1% 2·8% 6·2% ··
95% CI 25·6–45·4 1·8–4·2 4·7–7·9 ··
Number of operations per screen positive 2·9 35·2 16·2 ··
*Fisher’s exact test. †Includes borderline and ovarian neoplasm of uncertain behaviour. ‡Due to very large sample sizes 
the p values tend to imply statistically signiﬁ cant diﬀ erence where clinically meaningful diﬀ erence is minimal. 
§Borderline epithelial ovarian cancers and ovarian neoplasms of uncertain behaviour treated as false positives.
Table 6: Performance characteristics for detection of malignant ovarian and tubal neoplasms (ICD-10 C56 
and C57.0) in the prevalence screen 
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ovarian cancers share common morphological features 
on ultrasound imaging.29 The novel design of UKCTOCS, 
which randomly assigns women to two very diﬀ erent 
screening strategies, provides some insight into the 
extent of overdiagnosis inherent in the diﬀ erent 
screening strategies. The results indicate that 
pseudodisease will be less apparent with a serum CA125-
based ovarian cancer screening strategy than with USS 
screening. This accords with results from the prevalence 
screen of the Prostate Lung Colon Ovarian Cancer 
(PLCO) screening trial, in which only one of nine 
borderline ovarian neoplasms were detected by CA125 
screening, whereas all nine were detected by ultrasound.23 
There is a possibility that some of these borderline 
tumours may progress to invasive cancers if undetected, 
although there is little evidence to support this. 
Diﬀ erences between the screening groups on later 
follow-up should help to elucidate the issue, and allow 
deﬁ nite estimates of overdiagnosis to be calculated.
Given the issues surrounding borderline disease, a 
separate analysis was done excluding borderline lesions, 
eﬀ ectively treating such lesions as false positives. This 
resulted in a fall in the sensitivity of the USS screen from 
about 85% to 75%, with an attendant increase in the ratio 
of operations per true positive from 19:1 to 35:1. The 
detection rates in the MMS group remained at around 
89%, with a small increase in the ratio of operations per 
true positive from 2·3:1 to 2·9:1. Unlike speciﬁ city, the 
diﬀ erence in sensitivity between the two screening 
groups was not statistically signiﬁ cant (table 6). However, 
the clinical eﬀ ect of this diﬀ erence will depend on the 
mortality eﬀ ect on follow up, and on issues such as 
patient satisfaction and acceptability.
Various factors may contribute to the detection of more 
primary invasive epithelial cancers in the MMS group 
than in the USS group. Most notably, the MMS strategy 
incorporates follow-up of women initially classiﬁ ed as 
intermediate risk with repeat CA125 tests for a period of 
8–10 months. 21·4% (nine of the 34) of the cancers in the 
MMS group were identiﬁ ed via this pathway. It is possible 
that a transvaginal ultrasound scan done at the time of 
the level 1 screen, 7·5 months earlier than when the 
transvaginal ultrasound scan was actually done in these 
women, would not have detected an abnormality. 
Although an unsatisfactory scan in the USS group does 
lead to a repeat level 1 scan in 3 months, the follow-up is 
not equivalent to that of an intermediate risk of ovarian 
cancer, as women are returned to annual screening after 
two unsatisfactory scans but have continued follow-up 
with CA125 after two intermediate risk of ovarian cancer 
results. Ultrasound, unlike CA125, has a subjective 
element, and it is possible that the heightened awareness 
of a sonographer in view of rising CA125 concentrations 
contributed to a positive diagnosis. However, it is 
noteworthy that two of the nine women in the MMS 
group who were diagnosed after initially being classiﬁ ed 
as intermediate risk had normal scans initially. In one of 
these women surgery was done on the basis of a severe 
risk of ovarian cancer classiﬁ cation despite a repeat 
normal ultrasound scan. A detailed analysis of all the 
cancers detected in both groups is underway, and might 
shed more light on this issue.
Van Nagell and 
colleagues,9 2007
Kobayashi and 
colleagues,22 2008
PLCO,23 2005 UKCTOCS USS group UKCTOCS MMS group
Study design Single-arm 
prospective study
RCT with one 
screening strategy 
in study group
RCT with one 
screening strategy 
in study group
RCT with two screening 
strategies in the study 
group
RCT with two screening 
strategies in the study 
group
Screening strategy Ultrasound Physical exam, 
ultrasound, and 
CA125
Ultrasound and 
CA125
Ultrasound CA125 interpreted by 
ROC algorithm
Number of women screened 25 327 41 688 28 816 48 227 50 078
Mean number of screens per women 4·8 5·4 1 (ﬁ rst) 1 (ﬁ rst) 1 (ﬁ rst)
Number of women who had surgery 364 903 570 845 97
Primary epithelial ovarian and tubal cancers (ICD-10 C56, C57.0)* 
Number of women with primary epithelial ovarian and tubal cancers 39 27 27 45 42
Interval (missed) cancers diagnosed within 1 year of screen 9 8 † 8 5
Apparent sensitivity 81% 77% ‡ 85% 89%
Operations per cancers listed above detected 9·3 33·0 21·1 18·8 2·3
Number of borderlines or low malignant potential tumours 10 † 9 20 8
Outcome measure: primary invasive epithelial ovarian and tubal cancers (within 1 year of screen)
Apparent sensitivity 76·3% ‡ ‡ 75·0% 89·5%
Speciﬁ city 98·7% ‡ 98·4% 98·3% 99·9%
Number of operations per cancer detected 9·3 ‡ 21·1 35·2 2·9
% of stage I/II cancers among screen-detected cancers 82·1% ‡ 22·2% 50·0% 47·1%
*Excludes primary peritoneal cancers and non-epithelial ovarian neoplasms to allow comparison with Kobayashi et al, 2008. †Cannot be calculated owing to an absence of data. ‡Absent data.
Table 7: Comparison of outcomes of diﬀ erent ovarian cancer screening strategies in recent general population trials
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Diﬀ erences between the tests themselves could also 
lead to diﬀ erences in the detection of primary invasive 
epithelial cancers. Serum CA125 is a highly reproducible 
assay, and in this trial all measurements were done in one 
central accredited laboratory, which was subject to external 
quality control. By contrast, ultrasound has a subjective 
element, and accuracy is correlated with the experience of 
the sonographer.30,31 There are no described quality-
assurance measures for scanning postmenopausal ovaries 
in asymptomatic women. Measures have been developed 
in the course of the trial based on visualisation rates and 
ovarian volume, and validation of these measures is 
underway. More than 100 sonographers were required to 
deliver the scan load of 55 000 scans per year; these 
individuals were fully certiﬁ ed staﬀ  working in ultrasound 
departments in the UK NHS. They were required to 
undertake regular training, audit, and feedback as part of 
the trial. However, there will be a degree of heterogeneity 
between sonographers given the size of the trial. This is 
being analysed and will be reported elsewhere. Until then, 
it should be noted that the number of interval cancers 
and sensitivity in the USS group is in keeping with other 
large single-centre and multicentre series (table 7) for 
which systematic follow-up and tracing of interval cancers 
has been undertaken. In the MMS group, all scans were 
undertaken by very experienced type 2 specialists. 
The higher overall rates of surgery in the USS group 
primarily reﬂ ect the high prevalence of benign adnexal 
lesions in postmenopausal women. A previous ultra-
sound and autopsy study found that 15·4% of 
234 post menopausal women who had died from non-
gynaecological diseases had ovarian cysts.32 Here, 1894 
(3·9%) of women were found to have abnormal scans. 
Clinical assessment in the USS group, which included 
the use of morphological features detected during 
ultrasound, serum CA125, and other imaging modalities, 
decreased surgical rates to 44·6% (845 of 1894) of those 
found to have abnormalities compared with 58·1% (97 
of 167) of those with abnormalities in the MMS group 
(table 2). The lack of follow-up data on the outcome of 
pelvic masses with benign ultrasound morphology33 
means that a proportion of women and clinicians will 
opt for surgery once a complex adnexal lesion is detected, 
even if it is more likely to be benign. This is exempliﬁ ed 
in this series, in which a lesion detected on ultrasound 
was not removed on laparoscopy because it was thought 
to be an ovarian ﬁ broma (table 2). On follow-up 
22 months later it had increased in size and a stage IC 
papillary serous cystadenocarcinoma was diagnosed at 
surgery. The higher proportion of laparoscopic 
procedures in the USS group than in the MMS group 
(62·4% vs 28·6%) reﬂ ects the lower suspicion of 
malignancy among clinicians for certain ultrasound-
detected lesions. However, such decisions are not 
straightforward, as the risk of malignancy associated 
with lesions such as multilocular cysts in clinical series 
is 18%, rising to 49% if a solid component is also 
present.29 During further rounds of screening there is 
likely to be a substantial fall in the number of women 
undergoing surgery for benign lesions in the USS group, 
as most will have been removed or detected and managed 
conservatively during the prevalence screen. It is 
therefore important to wait for the results of incidence 
screening before drawing deﬁ nite conclusions about the 
positive-predictive value and speciﬁ city characteristics of 
the two screening strategies. In the  ultrasound screening 
trial by Van Nagell and colleagues,9 the number of 
operations per case of invasive epithelial ovarian cancer 
detected was 9·3:1 (table 7) after a mean of 4·8 annual 
screens. 2·9% of women undergoing surgery which 
resulted in benign pathology or normal ovaries being 
detected, experienced a major complication involving 
injury to a hollow viscus or signiﬁ cant haemorrhage. 
There was no diﬀ erence in the complication rates in the 
two screening groups.
The proportion of primary invasive ovarian and 
fallopian tube cancers diagnosed with stage I/II disease 
(48%) was encouraging compared with the 26% rate in 
the clinical series34 and 22% in the prevalence screen of 
the PLCO screening trial in the USA (table 7).23 The 
highest reported proportion of early-stage cancers 
detected on screening is from the University of Kentucky 
screening programme,9 where 82% of primary invasive 
epithelial ovarian cancers detected were stage I/II. 
However, these were the combined results of prevalence 
and incidence screening, with each woman in the study 
having had a mean of 4·8 scans. The overall number of 
ovarian cancers reported in the University of Kentucky 
study was also lower (table 7).9 The eﬀ ect of this apparent 
stage shift on mortality will not be known until suﬃ  cient 
events have accrued for a comparison with mortality in 
the control group, when the trial is completed in 
December, 2014. The false negatives were mostly 
diagnosed with stage I/II disease in the MMS group, and 
all with stage III/IV disease in the USS group. Numbers 
are too small at present to draw any meaningful 
conclusions, but with data from incidence screening it 
should be possible to investigate this further. 
The diﬀ erences in the uptake of the initial screen 
between women randomly assigned to the MMS group 
and USS group (ﬁ gure 1) must be interpreted with care. 
It is important not to interpret this as indicating that 
women preferred a blood test to a scan, as a signiﬁ cant 
proportion of this diﬀ erence reﬂ ects trial design. At 
recruitment, all women donated a blood sample. In 
women randomly assigned to the MMS group, this was 
assayed for CA125. However, women randomly assigned 
to the USS group had to attend again for their scan, and 
therefore had an opportunity to withdraw. Analysis of the 
psychosocial data and compliance with annual screening 
will provide better measures of womens’ preferences.
A limitation of trial design could be that the criteria 
used to classify scans did not incorporate one of the 
many weighted morphological indices that have been 
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proposed to improve discrimination between benign 
and malignant masses.29,35 However, it is important to 
note that most of these indices were derived from 
clinical series in symptomatic patients, in whom 
advanced cancers are the norm. Data on morphological 
characteristics of early ovarian cancers in asymptomatic 
patients and outcome on long-term follow-up of 
ultrasound-detected lesions are limited. Simple 
unilocular cysts are an exception, for which long-term 
follow-up of women has shown that they are invariably 
benign.36 This was incorporated into the UKCTOCS trial 
design, with simple cysts less than 60 cm³ in size 
classiﬁ ed as normal and the women returned to annual 
screening with no further review. In the absence of 
robust data on the long-term outcomes of all other 
complex lesions, any woman with a complex lesion was 
assessed individually. All clinicians were provided with 
pictorial depictions of complex morphology, initially 
using the Kentucky format19 until the adoption in 2003 
of the IOTA format,13 and all clinicians were aware of the 
risk of malignancy associated with the features in the 
clinical series. 
Another issue often raised is the current relevance of 
the screening strategies, which were designed in 1999. 
Serum CA125 and transvaginal ultrasound remain at the 
core of all new screening and diagnostic strategies being 
proposed for ovarian cancer, and although many new 
markers have been discovered since 1999, none have so 
far been validated in a prospective screening trial. 
However, it is hoped that this will change in the next few 
years. The trial serum bank, which currently has over 
350 000 samples, will make the retrospective testing of 
new markers possible.
A ﬁ nal limitation of this report is that no data are 
available on cancers in the control group. However, in 
line with other ovarian cancer screening randomised 
controlled trials,23 it was felt by the overseeing committees 
that the release of such information when screening is 
ongoing would compromise the overall outcome of the 
trial. These data should be available soon after screening 
is completed in 2011, ahead of the mortality analysis, 
which will require follow up until 2014. 
Women were invited from the age and sex registers of 
participating Primary Care Trusts. Although this 
maximises external validity by excluding biases related 
to advertisement and self-referral, the cohort is still 
likely to be healthier than the general UK population 
because of the characteristics of the women who chose 
to respond. The healthy-volunteer eﬀ ect is likely to 
result in a lower incidence of ovarian cancer deaths in 
the study population than in the entire UK population. 
However, there is no reason to believe that the ovarian 
cancers that occur in this cohort would be any diﬀ erent 
to those in the general population. The multicentre 
design, NHS hospital setting, use of standard tests 
(CA125 and transvaginal ultrasound) done by staﬀ 
similar to those who would deliver a national 
programme, and the management of women with 
abnormalities in NHS clinics using national guidelines 
ensures that the ﬁ ndings of the trial are applicable to 
the wider population. 
The results of the prevalence screen of the UKCTOCS 
show that both screening strategies are feasible. There 
are inherent diﬀ erences between the two strategies 
being tested, with a more subjective element inherent 
in the ultrasound-based strategy than with the CA125 
test, for which it is easy to implement stringent quality 
control. However, both screening strategies have 
encouraging performance characteristics. MMS has 
signiﬁ cantly better speciﬁ city than does USS, resulting 
in fewer repeat tests and less surgery; sensitivity for the 
detection of primary epithelial cancers of the ovaries 
and fallopian tubes seems better with MMS than with 
USS, although the diﬀ erence is not statistically 
signiﬁ cant. Overdiagnosis of borderline cancers seems 
to be less of a problem with MMS than with USS. 
Analysis of the psychosocial eﬀ ect and cost-eﬀ ectiveness 
of these strategies is currently underway. The results of 
ongoing screening are required before a conclusion can 
be drawn regarding the eﬀ ect of screening on 
mortality.
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